Wed.Feb 26, 2025

article thumbnail

2025 SALON TODAY 200: Customer Service

Salon Today

It's Day 2 of our 2025 SALON TODAY 200 reveal, and time to tip our hats to those salons who are always searching for ways to improve the client experience, including the fun-loving team from Little Fern Salon in

article thumbnail

Diamant Thaçi, MD, PhD: Understanding the Impact of Nemolizumab Efficacy Post Approvals in EU, UK, and Switzerland

Dermatology Times

Professor Diamant Thai, MD, PhD, discusses findings from the ARCADIA and OLYMPIA clinical trial programs, highlighting nemolizumabs rapid efficacy in treating atopic dermatitis and prurigo nodularis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Questex’s 2025 International Beauty Shows Announce Groundbreaking Partnership with Industry Sensation Live Fashion Hair

Beauty Launchpad

LIVE025 Pre-Launch will kick off at IBS NY and the Live Fashion Hair Awards (Americas Edition) will take place at IBS Las Vegas.

article thumbnail

Independent Pharmacy Overcomes Crisis with Community and Telehealth Help

Dermatology Times

Well Revolutions partnership with City Chemist highlights how telehealth can sustain small businesses and improve patient care.

article thumbnail

The best retinol products for your 50s, according to dermatologists

US Dermatologt Partners

Why is retinol important as you get older? Experts explain. Your fifties can be fabulous, but they can also come with a fresh set ofskin careconcerns as you enter a new decade. Fine lines andwrinklesare par for the course as you progress throughout life, and we like to think of them as signs of a life well-lived. But it’s only natural to crave a smoother complexion once these signs of aging start to creep up on you in your fifties.

Retinol 36
article thumbnail

Christophe Piketty, MD, PhD: Nemolizumab's Unique Mechanism of Action and Next Steps Globally

Dermatology Times

Christophe Piketty, MD, PHD, discusses the promising efficacy, novel mechanisms, and patient benefits of nemolizumab in targeting IL-31 for atopic dermatitis and psoriasis.

More Trending

article thumbnail

The Promise and Challenges of Augmented and Virtual Reality in Medicine

Dermatology Times

Lead investigator Leon Kircik, MD, emphasized the need for collaboration between clinicians, technologists, and policymakers to maximize VR/ARs potential.

41
article thumbnail

The Best Time to Get a Chemical Peel Your Cycle Holds the Answer.png

Enlightened Beauty

One of the biggest lessons Ive learned as an esthetician is that your skin isnt just reacting to your skincare routine, its responding to everything happening inside your body. Hormones play a major role in how your skin looks and feels throughout the month, which means the timing of your treatments matters. If youve ever noticed that some weeks your skin is clear and radiant while others bring unexpected breakouts or extra sensitivity, youre not imagining it.

article thumbnail

How Mindy Haws, MD, Empowers Women in Aesthetic Medicine

Dermatology Times

Haws offers advice to female clinicians about leadership, collaboration, and the future of the aesthetics industry.

36
article thumbnail

A deep dive into cosmetics preservatives with Dr Sabrina Behnke

The Eco Well Podcasts

This episode features a deep dive into the world of preservatives, featuring microbiologist Dr Sabrina Behnke. What are they, how and why are they used, how are they made, what are their supply chains like, what are formulation considerations we need to think about? And while a product may now be paraben free, how do those extra challenges impact product safety and sustainability?

article thumbnail

FDA Accepts Supplemental New Drug Application for Arcutis’ Roflumilast in Children with AD

Dermatology Times

A PDUFA target action date has been set for October 13, 2025.

41
article thumbnail

U.S. FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.05% (Zoryve) for Children Aged 2 to 5 with Mild-to-moderate AD; PDUFA Date Set

The Dermatology Digest

The U.S. Food and Drug Administration (FDA) accepted Arcutis Supplemental New Drug Application (sNDA) for roflumilast cream 0.05% (Zoryve) for the treatment of children aged 2 to 5 with mild-to-moderate atopic dermatitis (AD). The Prescription Drug User Fee Act (PDUFA) target action date is set for October 13, 2025. In clinical trials, investigational ZORYVE cream 0.05% has shown significant positive results in treating AD in children 2 to 5 years old.

Safety 36
article thumbnail

Journal Digest: February 26

Dermatology Times

This review of the latest dermatologic studies includes insights into

article thumbnail

Patients with Androgenetic Alopecia Have a Higher Risk of Depression

Dermatology Times

A two-set Mendelian randomization analysis revealed a genetic correlation between depression and androgenetic alopecia.

34